Belbuca buprenorphine buccal film: Phase II data

A double-blind, 2-way crossover Phase II trial in 35 confirmed opioid-dependent patients receiving once-daily around-the clock therapy with 80-220 mg doses of a full opioid agonist showed that switching to 300 and 400 ug doses of Belbuca -- calculated to be equivalent to 50% of their full agonist dose -- given about 8-12 hours after their last full opioid agonist dose led to no increase in the risk of experiencing opioid withdrawal or loss of pain relief. Significant withdrawal occurred in 1 patient in the Belbuca arm and in 2 patients in the full opioid agonist arm. Data were presented at the PAINWeek meeting in Las Vegas. ...